Unknown

Dataset Information

Targeting SARS-CoV-2 with Chaga mushroom: An in silico study toward developing a natural antiviral compound.


ABSTRACT: The novel coronavirus (SARS-CoV-2) has caused large-scale global outbreaks and mainly mediates host cell entry through the interaction of its spike (S) protein with the human angiotensin-converting enzyme-2 (ACE-2) receptor. As there is no effective treatment for SARS-CoV-2 to date, it is imperative to explore the efficacy of new compounds that possess potential antiviral activity. In this study, we assessed the potential binding interaction of the beneficial components of Chaga mushroom, a natural anti-inflammatory and immune booster with that of the SARS-CoV-2 receptor-binding domain (RBD) using molecular docking, MD simulation, and phylogenetic analysis. Beta glycan, betulinic acid, and galactomannan constituents of Chaga mushroom exhibited strong binding interaction (-7.4 to -8.6 kcal/

SUBMITTER: Eid JI 

PROVIDER: S-EPMC8645752 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature